DMIIU
NONEDrugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts)
Live · NASDAQ · May 9, Close
What's Moving DMIIU Today?
No stock-specific AI insight has been generated for DMIIU yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
DMIIU News
5 articles- NexGen Energy’s Rook I Project Emerges as a Key Source in the Next Uranium Supply WaveMotley Fool·Feb 24, 2026
- Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the companyYahoo Finance·Dec 4, 2025
- Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025Yahoo Finance·Dec 3, 2025
- Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public OfferingYahoo Finance·Sep 26, 2025
- Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public OfferingYahoo Finance·Sep 25, 2025
All 5 articles loaded
Price Data
Fundamentals
Trading
About Drugs Made In America Acquisition II Corp - Units (1 Ord Shs & 1 Rts)
Drugs Made In America Acquisition II Corp. (DMIIU) is a special purpose acquisition company (SPAC) dedicated to merging with and advancing companies within the pharmaceutical and biotechnology industries. The firm focuses on enhancing domestic drug manufacturing and fostering innovation in healthcare by strategically investing in entities with disruptive technologies and proven operational excellence. With a commitment to tackling critical industry challenges, DMIIU is well-positioned to generate substantial shareholder value while contributing to the evolution of the American healthcare landscape.